Clinical Trials
25 trialsMeasuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
National Cancer Institute (NCI)
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
National Cancer Institute (NCI)
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
National Cancer Institute (NCI)
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
ANNOUNCE
Eli Lilly and Company
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
TOASTIT
Mayo Clinic
TTI-621-03
Pfizer
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
OHSU Knight Cancer Institute
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
Masonic Cancer Center, University of Minnesota
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Children's Oncology Group
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
GEIS-27
Broto, Javier MartÃn, M.D.
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma
National Cancer Institute (NCI)
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
National Cancer Institute (NCI)
Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma
M.D. Anderson Cancer Center
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC